Clinical Trial

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-12-11; most recent amendment 2026-06-11.
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06735248
Lead Sponsor ModernaTX, Inc.
Conditions Multiple Sclerosis
Enrollment 180 participants
Start Date 2025-04-16
Primary Completion 2029-01-08 (estimated)
Study Completion 2029-01-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-15